Aim The study set out to better understand the epidemiology, natural history, therapeutic management and outcomes associated with confirmed human cases of Avian Influenza (AI) in Indonesia Methods This observational study utilized data from 93 cases with laboratory-confirmed H5N1 Influenza between September 2005 and August 2009. Cases were identified through records obtained from the Ministry of Health, as well as the Provincial health office and district health office records. Categorical data were analyzed with frequency tables, chi-square tests, and relative risks, and continuous data were analyzed using univariate statistics and Wilcoxon tests.
With the emergence and global spread of influenza H1N1 in 2009, global attention has shifted from avian influenza H5N1. Yet H5N1 remains endemic in many countries, notably in Asia, while outbreaks in poultry continue to occur. H5N1 remains a public health challenge. Indeed, some have argued that the risk of a global pandemic with very high mortality rates may be greater given the greater potential for re-assortment of H5N1 with H1N1. 1 Indonesia remains the country that has reported the greatest number of human cases of H5N1 2 
.
There have been 442 laboratory-confirmed cases of highly-pathogenic human avian influenza (H5N1) reported to WHO from 15 countries from November 2003 through September 2009. Indonesia reported 32% of the cases, with a case fatality rate of 81%, compared to 49% for the other 14 countries.
Given the high rate of human H5N1 cases in Indonesia and the considerably higher case fatality rate compared to other countries, 3 we undertook an analysis to better understand the natural history, risk factors, therapeutic management, and outcomes associated with confirmed cases of human avian influenza in Indonesia. It is hoped that a better understanding of these factors will lead to: better disease prevention, management and outcomes, and better evidence for health system policy formulation.
METHODS
Data on confirmed human avian influenza (H5N1) cases reported to the Indonesian Ministry of Health for the period 1
st Jan 2005 to 31 st May 2009 were collected from 3 provinces that documented the greatest number of H5N1 cases: Jakarta, Banten, and West Java. All cases had laboratory confirmation of human H5N1 influenza, and met the Ministry of Health case definition, which included the presence of a fever greater than 38 degrees Celsius, plus one of the following symptoms: cough, sore throat, headache, myalgia, conjunctivitis, dyspnoea, diarrhoea, GI tract disorder, and malaise. Laboratory confirmation consisted of one of the following: isolation of influenza A H5N1 virus; influenza A H5N1 detected by PCR; increase neutralizing antibody titer of H5N1 and convalescent specimen compared to acute specimen, and convalescent titer neutralizing antibody titer of 1/80 or greater; or neutralizing antibody titer of H5N1 of 1/80 or more on serum specimen on day 14 or later after onset. 4 This observational study 5 used data which were collected sequentially, starting with cases reported to provincial and district health offices. Data were abstracted from the Epidemiology Investigation Reports (EIR) 6 obtained from provincial and district offices onto a structured data collection sheet. Data sheets that were used to inform the EIRs were also reviewed. Data included name, sex, date of birth, address, educational attainment, contact history with poultry and persons, course and chronology of diseaserelated events including fever, pulse, respiratory rate, laboratory tests including hemoglobin, platelets, leucocytes, haematocrit, SGOT, SGPT), presence of pneumonia, signs and symptoms (cough, fever, dyspnoea, sore throat, headache, malaise, level of consciousness, vomiting), date of diagnosis, treatment dates and doses (antivirals, antibiotics, antipyretics, expectorants, analgesics), hospital admission and discharge dates, information on referral to hospitals, ventilator requirements, 7 and either copies of X-rays or X-ray reports. 8 Other data collected included data on risk factors (people whom the case had contacted, number and nature of contacts with poultry in preceding week, condition of the poultry with which there was contact, distance from poultry market, and distance from dead poultry). Maps of residential areas and distances to identified risk factors were plotted where known.
Data abstracted from the EIRs was verified, and additional data was retrieved, from medical records obtained from the health facilities. Data on progress was recorded including clinical status, progress, treatment, and results of investigations. The Ministry of Health Epidemiology Investigation Report (EIR) data sheets were informally reviewed to verify data from province and district offices. All data collected were entered into structured data collection forms.
In summary, data were retrieved and verified from 4 sources: 1) District and provincial EIR; 2) primary data collection sheets at district and province offices; 3) clinical records; 4) Ministry of Health EIR. When discrepancies in data collected from different sources existed, the data identified from the clinical medical record was used as the most reliable source data. Treatment with oseltamivir was documented if noted in any recorded source. However, since clinical record data were not always available or complete, treatment was analyzed as "documented" or "not documented" since treatment may have been provided but not documented in the available data sources. The analysis is descriptive. Categorical data were analyzed with frequency tables, chi-square tests, and relative risks, and continuous data were analyzed using univariate statistics and Wilcoxon tests. 
RESULTS
There were only 93 laboratory confirmed cases of human H5N1 avian influenza from 3 provinces in Indonesia between September 2005 and August 2009 were analyzed. Case characteristics are presented in Table 1 . The median age at onset was 18 years (range 1 to 67 years), and 51% of cases were female. The majority (54%) of patients first presented to a physician's office or clinic for medical care, and the predominant symptom at presentation was respiratory (85%). All patients were hospitalized. The only antiviral documented as treatment in this population was oseltamivir, and 25 subjects (27%) were documented as having been treated with oseltamivir. The overall case fatality rate was 89%. Cause of death was reported as pneumonia in 42 subjects (44%) and acute respiratory distress syndrome (ARDS) or progressive respiratory failure in 21 subjects (22%).
Of the 85 subjects for whom exposures were documented, the most common exposure was having been in the vicinity of live poultry, such as visiting a live poultry market (36%) ( Table 1 ). The second most common route of exposure was to poultry confirmed or suspected as having been infected with avian influenza (30%), including slaughtering, handling excrement, consuming, or having other direct contact with such poultry, or having poultry deaths in the home. Only 5 subjects (5%) reported having been exposed to a human case of AI, with three having had some form of exposure to poultry. Having direct poultry exposure appeared to increase the likelihood of a case being treated with oseltamivir ( Table 3) . Additional information regarding timing of documented oseltamivir treatment and survival is presented in table 4. For the 25 cases that were reported to have been treated with oseltamivir, the median time from symptom onset to presentation for medical care was similar in both treated cases who survived and those who died, and most often occurred within one day after onset of symptoms. In contrast, the median time from presentation to initiation of treatment, was shorter in survivors (2.5 days) compared to those who died (5 days). The time from symptom onset to start of antiviral treatment was shorter in those who survived (2.5 days) compared to those who died (7.0 days). Interpretation of the median times presented for treated survivors must be made with caution, given that there were only three surviving treated cases, and of those, treatment start date was only available for 2 cases. Case fatality rate by time from symptom onset to the start of oseltamivir treatment is presented in Figure 1 . Both treated survivors received oseltamivir within five days from symptom onset, whereas all 14 subjects treated after day six died. 
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Synopsis:
The epidemiology data suggest that early diagnosis and early treatment with the antiviral drug oseltamivir may play an important role in survival for Human Avian Influenza cases. 
DISCUSSION
The human disease resulting from H5N1 is associated with very high mortality rates in Indonesia. More than half of cases present with respiratory symptoms but a significant minority had gastrointestinal symptoms and a small minority present with only fever, similar to other reported case series. 10, 11 Patients present first to a number of clinical settings, most usually a physician's office but also emergency rooms and rural health centers. Whilst poultry exposure was not, in our analysis, a predictor of survival, it was associated with treatment with oseltamivir suggesting that a higher index of clinical suspicion for H5N1 occurs in clinicians when the patients report contact with poultry. This concurs with the reports suggesting better clinical outcomes in patients that are part of clusters of cases where clinical suspicion is likely to be high. 12 Whilst survival was not statistically significantly associated with treatment with oseltamivir, delays in the initiation of treatment occurred in many cases. Early treatment was associated with increased survival, but importantly early presentation for clinical care was not because of delays in initiating treatment with oseltamivir. Thus, the implication is that early treatment is important in achieving clinical success and a high index of clinical suspicion is necessary for patients presenting, sometimes with non-specific symptoms, to clinical settings. Where the incidence of disease is low, this remains a profound challenge. Whilst, awareness by clinicians of disease in the animal health sector might raise clinical suspicion in cases associated with poultry most clearly, 11 the awareness also has the potential to lower clinical suspicion in cases not reporting contact with poultry. These findings concur broadly with the clinical research from other case series reported recently, [11] [12] [13] [14] and offer further evidence building notably on the case series of Kandun et al. reported from Indonesia through an extension of the cases previously reported to include more recent cases from three provinces in Indonesia. 11 There are some limitations to this study. The sample size was small and few patients received treatment, and even fewer received early treatment restricting the ability to uncover significant variables. We did not collect data on the clustering of cases or determine quantitatively severity of disease at presentation, both of which among other variables may confound results.
Human AI in Indonesia is a highly lethal infection, with a high case fatality rate. 3 In cases unable to access antiviral treatment the case fatality rate appears to be more than 90%. Though the number of survivors in this study was small, these data suggest that early treatment with oseltamivir may yet have substantial benefit in terms of survival. For these benefits to accrue, clinical suspicion needs to be raised among physicians and other care-givers as the disease is likely to remain a profound challenge when the incidence is low and in a country with many other pressing public health problems. A clear policy for the protocol of early diagnosis & treatment of febrile illness including influenza is clearly necessary.
